FDA Issues CRL to Abeona for Potential RDEB Cell Therapy
Abeona's pz-cel is up for indicated use to treat patients with recessive dystrophic epidermolysis bullosa.
Amy Paller Peter Marinkovich Joyce Teng Kunzmannk Amy Paller Stanford University Drug Administration
Source: hcplive.com